Skip to content

Study · Animal study (in vivo) · dog · 2013

4 results

Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.

Oda H, Mori A, Lee P, Saeki K, Ishioka K, Arai T, Sako T

Research in veterinary science28 Apr 2013Cited by 7 (Europe PMC)

PMID23632200 (opens in a new tab)DOI10.1016/j.rvsc.2013.04.003 (opens in a new tab)PepBankPUB-23632200
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In healthy dogs, liraglutide stabilized glucose levels and reduced glucose AUC0-120 min by 13.8% versus baseline control during an oral glucose tolerance test.

    In plain wordsIn healthy dogs, liraglutide lowered blood sugar after a glucose drink by 13.8% compared with baseline.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlucose AUC0-120 min during OGTT
    Study

    dogn = 5

    Healthy dogs, oral glucose tolerance test
    Comparator
    Baseline control
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injectionAs given in this study (dog).

    Measurements

    Reduction in glucose AUC0-120 min
    13.8%
    healthy dogs

    Source sentences

    Summary
    Overall, liraglutide had a stabilizing effect on glucose levels, maintaining circulating levels between 77.0 and 137.0mg/ml throughout the OGTT test period, resulting in a significant reduction of 13.8% in glucose AUC0-120 min (total area under the curve for 0-120 min) as compared to baseline contro…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In healthy dogs, the liraglutide-associated glucose reduction was not accompanied by a significant increase in insulin.

    In plain wordsIn healthy dogs, liraglutide lowered blood sugar without a significant rise in insulin.

    Peptide
    Liraglutide
    Outcome
    No significant changeInsulin during OGTT
    Study

    dogn = 5

    Healthy dogs, oral glucose tolerance test
    Comparator
    Baseline control
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · injectionAs given in this study (dog).

    Source sentences

    Summary
    Interestingly, the liraglutide associated reduction in circulating glucose was not accompanied by any significant increase in insulin.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In dogs with type 1 diabetes, adding liraglutide to insulin reduced glucose AUC0-12h by 46.0% versus insulin treatment only.

    In plain wordsIn dogs with type 1 diabetes, liraglutide added to insulin lowered blood sugar over 12 hours by 46.0% compared with insulin alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlucose AUC0-12h in type 1 diabetes
    Study

    dogn = 4

    Dogs with type 1 diabetes mellitus on insulin
    Comparator
    Baseline control (insulin only)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injectionAs given in this study (dog).

    Measurements

    Reduction in glucose AUC0-12h
    46%
    T1DM dogs

    Source sentences

    Summary
    Moreover, T1DM dogs (n=4) responded favorably to liraglutide treatment, which lead to a significant reduction of 46.0% in glucose AUC0-12h (total area under the curve for 0-12h), and a significant reduction of 66.5% in serum glucose as compared to baseline controls (insulin treatment only).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In dogs with type 1 diabetes, adding liraglutide to insulin reduced serum glucose by 66.5% versus insulin treatment only.

    In plain wordsIn dogs with type 1 diabetes, liraglutide added to insulin lowered serum blood sugar by 66.5% compared with insulin alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseSerum glucose in type 1 diabetes
    Study

    dogn = 4

    Dogs with type 1 diabetes mellitus on insulin
    Comparator
    Baseline control (insulin only)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injectionAs given in this study (dog).

    Measurements

    Reduction in serum glucose
    66.5%
    T1DM dogs

    Source sentences

    Summary
    Moreover, T1DM dogs (n=4) responded favorably to liraglutide treatment, which lead to a significant reduction of 46.0% in glucose AUC0-12h (total area under the curve for 0-12h), and a significant reduction of 66.5% in serum glucose as compared to baseline controls (insulin treatment only).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.